Skip to content

ANDERA PARTNERS

Follow

13F filer, CIK 1757283, PARIS, France

ANDERA PARTNERS reported $175,700,568 across 7 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-10-16.

Accepted , ingested 13F-HR 0001757283-26-000022

Period
2026-09-30
Reported value
$176M
Holdings
7
Top 10 weight
100%
New
0
Sold out
1

Part of the filer group ANDERA PARTNERS

  • BioDiscovery 6 FPCI
  • Francois Xavier Mauron
  • Stephane Bergez
How groups are built

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
EVMNreduced-1,294,628-$10.7M
ABVXexited-78,125-$10.4M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001757283-26-000022, largest first. % of portfolio is the value over $175,700,568, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KMTSKESTRA MED TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 2,540,106 shares; 2026Q1: 2,695,192 shares; 2026Q2: 2,728,679 shares; 2026Q3: 2,728,679 shares 2,728,679$77.2M43.94%0Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,591,917 shares; 2026Q1: 1,591,917 shares; 2026Q2: 1,591,917 shares; 2026Q3: 1,591,917 shares 1,591,917$40M22.77%0Timeline
AVLNAVALYN PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 929,824 shares; 2026Q3: 929,824 shares 929,824$26.5M15.08%0Timeline
AGMBAGOMAB THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 1,538,702 shares; 2026Q2: 1,538,702 shares; 2026Q3: 1,538,702 shares 1,538,702$17.1M9.72%0Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,818,181 shares; 2026Q1: 1,818,181 shares; 2026Q2: 3,633,181 shares; 2026Q3: 3,633,181 shares 3,633,181$13.4M7.63%0Timeline
EVMNEVOMMUNE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: 1,897,362 shares; 2026Q1: 1,897,362 shares; 2026Q2: 1,391,990 shares; 2026Q3: 97,362 shares 97,362$804K0.46%-1,294,628Timeline
NYXHNYXOAH S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not loaded; 2025Q2: not loaded; 2025Q3: not loaded; 2025Q4: not reported; 2026Q1: 522,057 shares; 2026Q2: 522,057 shares; 2026Q3: 522,057 shares 522,057$720K0.41%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ABVXABIVAX SA78,125$10.4Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001757283-26-000022 base2026-10-16